Omipalisib
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Omipalisib
- DrugBank Accession Number
- DB12703
- Background
Omipalisib has been used in trials studying the treatment of CANCER, Solid Tumours, and Idiopathic Pulmonary Fibrosis.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 505.496
Monoisotopic: 505.102016535 - Chemical Formula
- C25H17F2N5O3S
- Synonyms
- Omipalisib
- External IDs
- GSK2126458
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as quinolines and derivatives. These are compounds containing a quinoline moiety, which consists of a benzene ring fused to a pyrimidine ring to form benzo[b]azabenzene.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Quinolines and derivatives
- Sub Class
- Not Available
- Direct Parent
- Quinolines and derivatives
- Alternative Parents
- Benzenesulfonamides / Benzenesulfonyl compounds / Alkyl aryl ethers / Fluorobenzenes / Pyridines and derivatives / Pyridazines and derivatives / Organosulfonamides / Aryl fluorides / Aminosulfonyl compounds / Heteroaromatic compounds show 6 more
- Substituents
- Alkyl aryl ether / Aminosulfonyl compound / Aromatic heteropolycyclic compound / Aryl fluoride / Aryl halide / Azacycle / Benzenesulfonamide / Benzenesulfonyl group / Benzenoid / Ether show 21 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 1X8F5A3NA0
- CAS number
- 1086062-66-9
- InChI Key
- CGBJSGAELGCMKE-UHFFFAOYSA-N
- InChI
- InChI=1S/C25H17F2N5O3S/c1-35-25-23(32-36(33,34)24-5-3-18(26)12-21(24)27)11-17(13-29-25)15-2-4-22-20(10-15)19(7-8-28-22)16-6-9-30-31-14-16/h2-14,32H,1H3
- IUPAC Name
- 2,4-difluoro-N-{2-methoxy-5-[4-(pyridazin-4-yl)quinolin-6-yl]pyridin-3-yl}benzene-1-sulfonamide
- SMILES
- COC1=C(NS(=O)(=O)C2=C(F)C=C(F)C=C2)C=C(C=N1)C1=CC2=C(C=CN=C2C=C1)C1=CN=NC=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 25167777
- PubChem Substance
- 347828901
- ChemSpider
- 25027388
- BindingDB
- 50145416
- ChEBI
- 95093
- ChEMBL
- CHEMBL1236962
- ZINC
- ZINC000043208634
- PDBe Ligand
- ZIG
- PDB Entries
- 3l08
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 1 Completed Treatment Idiopathic Pulmonary Fibrosis (IPF) 1 1 Completed Treatment Solid Tumors 1 1 Terminated Treatment Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00193 mg/mL ALOGPS logP 3.63 ALOGPS logP 3.22 Chemaxon logS -5.4 ALOGPS pKa (Strongest Acidic) 6.58 Chemaxon pKa (Strongest Basic) 4 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 106.96 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 129.84 m3·mol-1 Chemaxon Polarizability 48.29 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 204.33156 predictedDeepCCS 1.0 (2019) [M+H]+ 206.72713 predictedDeepCCS 1.0 (2019) [M+Na]+ 212.63966 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 23:41 / Updated at February 21, 2021 18:53